Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab), Merck & Co. Inc.’s reigning blockbuster cancer drug.
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Abbisko, Altamira, Astrazeneca, Boehringer, Cytokinetics, Daiichi Sankyo, Gensight, Hansa, Huonslab, Incyte, Kalvista, Merck & Co., Merck KGaA, PTC, Roche, Savara, Viridian.
In a letter to the hemophilia community, Pfizer Inc. reported a death due to cerebellar infarction and subsequent cerebral hemorrhage in a long-term extension trial participant taking the New York-based company’s tissue factor pathway inhibitor antagonist Hympavzi (marstacimab).
After being unanimously passed by the U.S. House Dec. 1, the bipartisan Mikaela Naylon Give Kids a Chance Act seemed to be headed for sure passage in the Senate before it adjourned late last week.
RSS
